KAIST Researchers Develop Next-Generation mRNA Platform to Overcome Efficacy Loss in Elderly and Obese Patients
核心洞察
KAIST (搜索) researchers have developed a next-generation mRNA (搜索) platform that maintains therapeutic efficacy in elderly and obese patients by precision engineering the 5' untranslated region (搜索) (5'UTR (搜索)) sequence.
The new mRNA (搜索) design significantly enhanced protein production and immune response in preclinical models of aging (搜索) and obesity (搜索), overcoming limitations of reduced efficacy in high oxidative stress (搜索) conditions.
This breakthrough technology is expected to be applicable to mRNA (搜索) vaccines, gene therapies, and immunotherapies, addressing a critical gap in therapeutic effectiveness for vulnerable patient populations.
A joint research team from KAIST (搜索) and Catholic University of Korea has developed a breakthrough mRNA (搜索) platform that maintains therapeutic efficacy in elderly and obese patients, addressing a critical limitation in current mRNA-based therapeutics. The research, published in Molecular Therapy on January 2, represents a significant advancement in overcoming reduced drug effectiveness in vulnerable patient populations.
Engineering the mRNA Regulatory Region
The research team, led by Professor Lee Young-seok from KAIST (搜索)'s Department of Bio and Brain Engineering and Professor Nam Jae-hwan from Catholic University of Korea, focused on precision engineering of the 5' untranslated region (搜索) (5'UTR (搜索)) sequence, a key regulatory region of mRNA (搜索) that initiates and regulates protein production efficiency.
"This research identified design methods that enable mRNA (搜索) to produce proteins more effectively by analyzing extensive biological data," said Professor Lee Young-seok. "This technology will serve as an important foundation for ensuring that mRNA vaccines and therapeutics work effectively even in environments where drug efficacy may be reduced, such as in elderly or obese patients."
Addressing Cellular Stress Challenges
The breakthrough addresses a fundamental challenge in mRNA (搜索) therapeutics: cells in elderly and obese individuals experience high levels of oxidative stress (搜索), which significantly impairs their protein-producing capabilities. Since existing mRNA drugs have primarily been tested for efficacy in young, healthy animals, their ability to maintain potency in stressful cellular environments has not been sufficiently verified.
The research team overcame this limitation by redesigning the 5'UTR (搜索) region to enhance therapeutic protein production efficiency across various cellular environments, particularly those characterized by high oxidative stress (搜索).
Comprehensive Data Analysis Approach
The development process utilized multiple advanced analytical techniques to identify optimal 5'UTR (搜索) sequences. The team integrated and analyzed various forms of biological big data, including large-scale tissue transcriptome analysis (RNA-seq) for measuring gene activity, single-cell transcriptome analysis (scRNA-seq) for examining gene expression at individual cell levels, and ribosome profiling (Ribo-seq) for measuring actual protein production efficiency.
This comprehensive approach enabled the researchers to identify 5'UTR (搜索) sequences with consistently high protein production capabilities across various tissues and cellular environments, leading to the design of superior mRNA (搜索) sequences.
Significant Preclinical Results
When the newly designed mRNA (搜索) therapeutics incorporating the identified high-performance 5'UTR (搜索) sequences were applied to preclinical models of aging (搜索) and obesity (搜索), the results demonstrated substantial improvements. The amount of protein produced by cells and the subsequent immune response were significantly enhanced compared to existing mRNA platforms.
Notably, while previously known 5'UTR (搜索) sequences showed reduced efficacy in aged or obese animals, the new sequence actually demonstrated a tendency to be more effective under these challenging conditions. The research team confirmed that this enhanced effect is mediated by the binding of protein factors called LARP1 (搜索) and LARP4 (搜索) to the redesigned 5'UTR.
Broad Therapeutic Applications
The implications of this research extend far beyond mRNA (搜索) vaccines. The technology is expected to be applicable to the development of various biopharmaceutical technologies, including gene therapies and immunotherapies, potentially revolutionizing treatment options for elderly and obese patient populations who have historically experienced reduced therapeutic benefits.
The research, with Dr. Yoon Su-bin of Catholic University of Korea and KAIST (搜索) doctoral student Cho Hyung-gon as co-first authors, was supported by multiple funding sources including the Ministry of Science and ICT's National Research Foundation of Korea's Excellent Young Researcher Program and Bio-Medical Development Project, the Ministry of Food and Drug Safety's Innovative Technology Support Research for Infectious Disease Response, and the Korea Health Industry Development Institute's Infectious Disease Prevention and Treatment Technology Development Project.